Research progress of radiotherapy dose pattern changes for pancreatic cancer

doi:10.3877/cma.j.issn.2095-3224.2016.02.03

Abstract

Abstract:

Pancreatic cancer is a highly malignant tumor and the prognosis is poor. Radiotherapy is an important treatment for pancreatic cancer. But the curative effect of the conventional dose mode to prolong the survival time of the patients is questioned. By changing dose model of radiotherapy, hypofractionated mode can improve the local control rate of the tumor, relieve pain, and maybe prolong the survival time in domestic and foreign literatures. In spite of this, the selection of the dose pattern, the protection of the organ, and how to combine with the operation in the high dose and low dose radiotherapy still need further explored.

Key words: Pancreatic neoplasms, Radiotherapy dosage, Research progress

Gang Ren, Tingyi Xia. Research progress of radiotherapy dose pattern changes for pancreatic cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(02): 121-126.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.02.03

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I02/121

References 39

[1]	Siegel RL, Miller KD, Jemal A.CA: a cancer journal for clinicians.Cancer statistics, 2015, 65(1): 5-29.
[2]	Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. Journal of clinical oncology, 2005, 23(20): 4538-4544.
[3]	Van den Broeck A, Sergeant G, Ectors N, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European journal of surgical oncology, 2009, 35(6): 600-604.
[4]	Hattangadi JA, Hong TS, Yeap BY, et al. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer, 2009, 115(16): 3640-3650.
[5]	Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Annals of surgery, 2006, 244(1): 10-15.
[6]	Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet, 2011, 378(9791): 607-620.
[7]	Loehrer PJSr, Feng Y, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Journal of clinical oncology, 2011, 29(31): 4105-4112.
[8]	Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Annals of oncology, 2008, 19(9): 1592-1599.
[9]	Hammel P, Huguet F, Van LJ-Lea. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. Journal of clinical oncology, 2013, 31(suppl): Abstr LBA4003.
[10]	Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. Journal of clinical oncology, 2011, 29(22): 3037-3043.
[11]	Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2004, 58(4): 1017-1021.
[12]	Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2008, 72(3): 678-686.
[13]	Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 2015, 121(7): 1128-1137.
[14]	Brunner TB, Nestle U, Grosu AL, et al. SBRT in pancreatic cancer: what is the therapeutic window? Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 2015, 114(1): 109-116.
[15]	Gurka MK, Collins SP, Slack R, et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiation oncology, 2013, 8: 44.
[16]	Kim CH, Ling DC, Wegner RE, et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiation oncology, 2013, 8: 240.
[17]	Rombouts SJ, Vogel JA, van Santvoort HC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. The British journal of surgery, 2015, 102(3): 182-193.
[18]	夏廷毅，孙庆选，于涌，等．体部r-刀治疗52例胰腺癌的疗效分析．中华肝胆外科杂志，2006，12(2): 86-88.
[19]	任刚，王竞，夏廷毅．《胰腺癌综合诊治中国专家共识(2014年版)》放疗部分解读．临床肝胆病杂志，2014，30(12): 1249-1252.
[20]	Taylor R, Opfermann K, Jones BD, et al. Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy. Journal of medical imaging and radiation oncology, 2012, 56(3): 332-337.
[21]	Xia T, Chang D, Wang Y, et al. Dose escalation to target volumes of helical tomotherapy for pancreatic cancer in the phase I-II clinical trial [abstract 2262]. International journal of radiation oncology, biology, physics, 2013, 87(2): S303.
[22]	Ren G, Xia TY, Di YP, et al. Hypofractionated and Simultaneous Integrated Boost Radiation Therapy for Locally Advanced Pancreatic Cancer With Helical Tomotherapy. International journal of radiation oncology, biology, physics, 2015, 93(3): E149-E150.
[23]	Rajagopalan MS, Heron DE, Wegner RE, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiation oncology, 2013, 8: 254.
[24]	Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. International journal of radiation oncology, biology, physics, 2013, 86(3): 516-522.
[25]	Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta oncologica, 2015, 54(7): 979-985.
[26]	Moningi S, Dholakia AS, Raman SP, et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Annals of surgical oncology, 2015, 22(7): 2352-2358.
[27]	Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the American College of Surgeons, 2008, 206(5): 833-846; discussion 846-838.
[28]	Lin JC, Jen YM, Li MH, et al. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer. European journal of gastroenterology & hepatology, 2015, 27(3): 259-264.
[29]	Crane C CA, Koay E, Varadhachary GR. Effect of dose-escalation of IMRT for unresectable pancreatic cancer 1 cm away from the luminal mucosa on long-term survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33 (suppl3) (3): abstr354.
[30]	Crane CH. Improving Long-Term Survival in Patients With Locally Advanced Pancreatic Cancer via the Delivery of Definitive Radiotherapy Doses. Oncology, 2015, 29(8): 561-562, 566.
[31]	Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2005, 63(2): 320-323.
[32]	Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 2005, 76(1): 48-53.
[33]	Passoni P, Reni M, Cattaneo GM, et al. Hypofractionated Image-Guided IMRT in Advanced Pancreatic Cancer With Simultaneous Integrated Boost to Infiltrated Vessels Concomitant With Capecitabine: A Phase I Study. International journal of radiation oncology, biology, physics, 2013, 87(5): 1000-1006.
[34]	Ren G Zhu FH, Xia TY, et al. Dosimetric study on dose escalation in internal target of pancreatic cancer with helical tomotherapy.International journal of radiation oncology, biology, physics, 2014, 90(1): S357.
[35]	Ford EC, Herman J, Yorke E, et al. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine, 2009, 50(10): 1655-1665.
[36]	McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2001, 19(22): 4202-4208.
[37]	Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer, 2009, 115(3): 665-672.
[38]	Murphy JD, Christman-Skieller C, Kim J, et al. A dosimetric model of duodenal to xicity after stereotactic body radiotherapy for pancreatic cancer, International journal of radiation oncology, biology, physics, 2010, 78(5): 1420-1426.
[39]	Cattaneo GM, Passoni P, Longobardi B, et al. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 2013, 108(1): 66-71.

Please choose a citation manager

Content to export